A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04740814 |
Recruitment Status :
Completed
First Posted : February 5, 2021
Results First Posted : November 13, 2023
Last Update Posted : February 12, 2024
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rheumatoid Arthritis | Drug: Certolizumab pegol | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 33 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | A Multi-Center, Open-Label Study to Evaluate the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Using an Electrochemiluminescent Immuno-Assay |
Actual Study Start Date : | February 11, 2021 |
Actual Primary Completion Date : | January 24, 2022 |
Actual Study Completion Date : | June 27, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Certolizumab pegol
Subjects in this arm will receive doses of certolizumab pegol for the treatment of Rheumatoid Arthritis, in accordance with the US label.
|
Drug: Certolizumab pegol
|
- Minimum Observed Plasma Concentration (Cmin) Post 10 Weeks of Certolizumab Pegol Dosing [ Time Frame: Plasma samples were collected at Pre dose on Day 70 (Week 10), 72, 75, 77 and 80 post-Week 10 study Investigational Medicinal Product (IMP) administration, and Pre dose on Day 84 (Week 12) ]Cmin is the Minimum observed plasma drug concentration during a dosage interval.
- Area Under the Concentration-time Curve Over One Dosing Interval (AUC0-tau) of Certolizumab Pegol [ Time Frame: Plasma samples were collected at Pre dose on Day 70 (Week 10), 72, 75, 77 and 80 post-Week 10 study IMP administration, and Pre dose on Day 84 (Week 12) ]AUCtau is the area Under the plasma concentration-time curve from time zero to tau for the dosing interval following administration at Week 10.
- Plasma Concentration of Certolizumab Pegol (CZP) During the Study [ Time Frame: Predose (Day 0), Day 7, 14, 42, 70, 72, 75, 77, 80, 84, 126, and 168 ]Plasma samples were taken at Predose and during the study at different pre and post dose time points for all participants.
- Percentage of Participants With Treatment-emergent Serious Adverse Event (SAEs) [ Time Frame: From Baseline to the Safety Follow-up Visit (up to Week 34) ]A treatment-emergent adverse event (TEAE) was defined as events that have a start date on or following the first administration of study treatment in this study through the final administration of study treatment+70 days through Safety Follow-up (SFU) visit. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: Results in death, Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity, Is a congenital anomaly or birth defect, Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.
- Percentage of Participants With Treatment-emergent Adverse Event (TEAEs) Leading to Withdrawal [ Time Frame: From Baseline to the Safety Follow-up Visit (up to Week 34) ]An Adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication. A TEAE was defined as events that have a start date on or following the first administration of study treatment in this study through the final administration of study treatment+70 days through Safety Follow-up (SFU) visit.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 69 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant must be 18 to 69 years of age inclusive, at the time of signing the informed consent
- Participant must have a diagnosis of moderately-to-severely active rheumatoid arthritis (RA)
- Participant must have had an inadequate response to, or intolerance to, at least 1 disease modifying antirheumatic drug (DMARD) (nonbiologic or biologic)
- Participant has a negative interferon-gamma release assay (IGRA) at Screening
- Participant has a body mass index within the range 18.0 kg/m2 to 35.0 kg/m2 (inclusive)
- Male or female
-
A female participant is eligible to participate if:
i) she is not pregnant, ii) not breastfeeding, iii) at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
-
A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and until the Safety Follow-up (SFU) Visit
Exclusion Criteria:
- Participant has a known hypersensitivity to any components of the study medication(including polyethylene glycol) or comparative drugs (and/or an investigational device) as stated in this protocol
- Participant has clinically significant electrocardiogram (ECG) abnormalities at Screening
- Participant has previously been exposed to certolizumab pegol (CZP)
- Participant has failed treatment with ≥1 tumor necrosis factor (TNF) α inhibitor or was a primary failure for any TNFα antagonist. A primary failure is defined as no clinical disease improvement within the first 12 weeks of treatment (study participants who demonstrated clinical response within 12 weeks of treatment and subsequently lost response after 12 weeks of treatment are eligible)
- Participant has received a live vaccination within 6 weeks prior to Screening or intends to have a live vaccination during the course of the study or within 3 months following CZP treatment in the study
- Participant has received any investigational drug or experimental procedure within 90 days prior to the first dose of IMPinvestigational medicinal product (IMP)
-
Participant has a laboratory abnormality at Screening, including any of the following:
- >3.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP); or >ULN total bilirubin (>1.5x ULN total bilirubin if the participant has a documented pre-study diagnosis of Gilbert's syndrome)
- white blood cell count <3.00x103/μL
- absolute neutrophil count (ANC) <1.5x103/μL
- lymphocyte count <500 cells/μL
- hemoglobin <8.5 g/dL
- Any other laboratory abnormality, which, in the opinion of the Investigator, will prevent the study participant from completing the study or will interfere with the interpretation of the study results
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04740814
United States, Arizona | |
Ra0138 1009 | |
Phoenix, Arizona, United States, 85032 | |
United States, California | |
Ra0138 1002 | |
Covina, California, United States, 91722 | |
Ra0138 1008 | |
Upland, California, United States, 91786 | |
United States, Florida | |
Ra0138 1015 | |
Palm Harbor, Florida, United States, 34684 | |
Ra0138 1004 | |
Plantation, Florida, United States, 33324 | |
United States, Kentucky | |
Ra0138 1001 | |
Lexington, Kentucky, United States, 40504 | |
United States, Maryland | |
Ra0138 1014 | |
Rockville, Maryland, United States, 20850 | |
United States, New Mexico | |
Ra0138 1005 | |
Albuquerque, New Mexico, United States, 87102 | |
United States, Pennsylvania | |
Ra0138 10025 | |
Duncansville, Pennsylvania, United States, 16635 | |
Ra0138 1003 | |
Duncansville, Pennsylvania, United States, 16635 | |
United States, Tennessee | |
Ra0138 1016 | |
Memphis, Tennessee, United States, 38119 | |
United States, Texas | |
Ra0138 1007 | |
Austin, Texas, United States, 78731 | |
Ra0138 1010 | |
Dallas, Texas, United States, 75231 | |
Ra0138 1011 | |
Tomball, Texas, United States, 77375 |
Study Director: | UCB Cares | 001 844 599 2273 (UCB) |
Documents provided by UCB Pharma ( UCB Biopharma SRL ):
Responsible Party: | UCB Biopharma SRL |
ClinicalTrials.gov Identifier: | NCT04740814 |
Other Study ID Numbers: |
RA0138 |
First Posted: | February 5, 2021 Key Record Dates |
Results First Posted: | November 13, 2023 |
Last Update Posted: | February 12, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Rheumatoid arthritis Phase 1 Cimzia Certolizumab pegol Electrochemiluminescent immune-assay |
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |
Certolizumab Pegol Tumor Necrosis Factor Inhibitors Anti-Inflammatory Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |